Yuichiro Ide1,2, Ryu Yanagisawa2,3,4, Jun Kobayashi5, Kazutoshi Komori6, Kazuyuki Matsuda7, Yuji Amano8, Yozo Nakazawa9, Toshikazu Takeshita8, Kazuo Sakashita6, Minoru Tozuka2,5. 1. Department of Laboratory Medicine, Shinshu University Hospital, Matsumoto, Japan. 2. Life Science Research Centre, Nagano Children's Hospital, Azumino, Japan. 3. Division of Blood Transfusion, Shinshu University Hospital, Matsumoto, Japan. 4. Centre for Advanced Cell Therapy, Shinshu University Hospital, Matsumoto, Japan. 5. Department of Laboratory Medicine, Nagano Children's Hospital, Azumino, Japan. 6. Department of Haematology and Oncology, Nagano Children's Hospital, Azumino, Japan. 7. Department of Clinical Laboratory Sciences, School of Health Sciences, Shinshu University, Matsumoto, Japan. 8. Department of Microbiology and Immunology, Shinshu University School of Medicine, Matsumoto, Japan. 9. Department of Paediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
Abstract
BACKGROUND: Allergic transfusion reactions (ATR) and febrile non-haemolytic transfusion reactions (FNHTR) are common transfusion-related adverse reactions; however, their pathogenesis remains unclear and it is difficult to predict their occurrence. Single-nucleotide polymorphisms (SNP) are related to the onset of various diseases and therapy-related adverse events; therefore, identification of SNP related to transfusion-related adverse reactions may help to elucidate the underlying mechanism and predict the onset of these reactions. MATERIALS AND METHODS: We retrospectively analysed the association between the onset of ATR or FNHTR and 22 allergic sensitisation-related SNP in 219 children (aged ≤20 years) who had haematological and oncological diseases and who had received transfusions of platelets and/or red blood cell concentrates. RESULTS: Among the 219 children, 105 had developed an ATR and/or FNHTR at least once. The patients who developed ATR frequently had a risk allele in rs6473223, while the patients who developed FNHTR frequently had a risk allele in rs10893845. Furthermore, patients who developed ATR accompanied by febrile symptoms also frequently had a risk allele in rs10893845, similar to patients who developed FNHTR. DISCUSSION: The results suggested that allergic sensitisation is associated with the onset of ATR and/or FNHTR in some patients. Although further prospective evaluation is necessary, analysis of these SNP might help to provide safer transfusion therapy by predicting patients at higher risk of transfusion-related adverse reactions and further clarifying the pathogenic mechanism underlying such reactions.
BACKGROUND: Allergic transfusion reactions (ATR) and febrile non-haemolytic transfusion reactions (FNHTR) are common transfusion-related adverse reactions; however, their pathogenesis remains unclear and it is difficult to predict their occurrence. Single-nucleotide polymorphisms (SNP) are related to the onset of various diseases and therapy-related adverse events; therefore, identification of SNP related to transfusion-related adverse reactions may help to elucidate the underlying mechanism and predict the onset of these reactions. MATERIALS AND METHODS: We retrospectively analysed the association between the onset of ATR or FNHTR and 22 allergic sensitisation-related SNP in 219 children (aged ≤20 years) who had haematological and oncological diseases and who had received transfusions of platelets and/or red blood cell concentrates. RESULTS: Among the 219 children, 105 had developed an ATR and/or FNHTR at least once. The patients who developed ATR frequently had a risk allele in rs6473223, while the patients who developed FNHTR frequently had a risk allele in rs10893845. Furthermore, patients who developed ATR accompanied by febrile symptoms also frequently had a risk allele in rs10893845, similar to patients who developed FNHTR. DISCUSSION: The results suggested that allergic sensitisation is associated with the onset of ATR and/or FNHTR in some patients. Although further prospective evaluation is necessary, analysis of these SNP might help to provide safer transfusion therapy by predicting patients at higher risk of transfusion-related adverse reactions and further clarifying the pathogenic mechanism underlying such reactions.
Authors: William J Savage; Aaron A R Tobian; Jessica H Savage; Robert A Wood; John T Schroeder; Paul M Ness Journal: Transfusion Date: 2012-09-24 Impact factor: 3.157
Authors: Milton Pividori; Nathan Schoettler; Dan L Nicolae; Carole Ober; Hae Kyung Im Journal: Lancet Respir Med Date: 2019-04-27 Impact factor: 30.700
Authors: Enrico Tiacci; Pier-Luigi Orvietani; Barbara Bigerna; Alessandra Pucciarini; Garry L Corthals; Valentina Pettirossi; Maria P Martelli; Arcangelo Liso; Roberta Benedetti; Roberta Pacini; Niccolò Bolli; Stefano Pileri; Karen Pulford; Marcello Gambacorta; Antonino Carbone; Carla Pasquarello; Alexander Scherl; Helen Robertson; Maria Teresa Sciurpi; Giovanni Alunni-Bistocchi; Luciano Binaglia; Jennifer A Byrne; Brunangelo Falini Journal: Blood Date: 2004-12-02 Impact factor: 22.113
Authors: Adam Auton; Lisa D Brooks; Richard M Durbin; Erik P Garrison; Hyun Min Kang; Jan O Korbel; Jonathan L Marchini; Shane McCarthy; Gil A McVean; Gonçalo R Abecasis Journal: Nature Date: 2015-10-01 Impact factor: 49.962